{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T19:46:08Z","timestamp":1792698368029,"version":"4.5.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,1,29]],"date-time":"2020-01-29T00:00:00Z","timestamp":1580256000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,1,29]],"date-time":"2020-01-29T00:00:00Z","timestamp":1580256000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100002855","name":"Ministry of Science and Technology of the People's Republic of China","doi-asserted-by":"publisher","award":["2019CB964400"],"award-info":[{"award-number":["2019CB964400"]}],"id":[{"id":"10.13039\/501100002855","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["AI 064569"],"award-info":[{"award-number":["AI 064569"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004032","name":"Jilin University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004032","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Cancer cells are poorly immunogenic and have a wide range of mutations, which makes them unsuitable for use in vaccination treatment. Here, we show that elimination of CD47, a ligand for the myeloid cell inhibitory receptor SIRP\u03b1, from tumor cells by genetic deletion or antibody blocking, significantly improves the effectiveness of the immune response to tumour cells. In both solid and hematopoietic mouse tumor models, vaccination with tumor cells or tumor antigen-expressing cells, that lack CD47 or were pre-coated with anti-CD47 antibodies, achieved an antitumor immune response. The efficacy of this approach was synergistically enhanced when used in combination with anti-PD-1 antibodies. The induction of antitumor responses depends on SIRP\u03b1<jats:sup>+<\/jats:sup>CD11c<jats:sup>+<\/jats:sup> DCs, which exhibit rapid expansion following introduction of CD47-deficient tumor cells. Our results indicate that CD47-deficient whole tumor cells can induce antitumor responses.<\/jats:p>","DOI":"10.1038\/s41467-019-14102-4","type":"journal-article","created":{"date-parts":[[2020,1,29]],"date-time":"2020-01-29T11:08:02Z","timestamp":1580296082000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":55,"title":["Vaccination with CD47 deficient tumor cells elicits an antitumor immune response in mice"],"prefix":"10.1038","volume":"11","author":[{"given":"Yang","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingyou","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaodan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wentao","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong-Guang","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,1,29]]},"reference":[{"key":"14102_CR1","doi-asserted-by":"publisher","first-page":"334ps339","DOI":"10.1126\/scitranslmed.aaf0685","volume":"8","author":"P Romero","year":"2016","unstructured":"Romero, P. et al. The Human Vaccines Project: a roadmap for cancer vaccine development. Sci. Transl. Med. 8, 334ps339 (2016).","journal-title":"Sci. Transl. Med."},{"key":"14102_CR2","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1126\/science.aaa4971","volume":"348","author":"TN Schumacher","year":"2015","unstructured":"Schumacher, T. N. & Schreiber, R. D. Neoantigens in cancer immunotherapy. Science 348, 69\u201374 (2015).","journal-title":"Science"},{"key":"14102_CR3","doi-asserted-by":"publisher","first-page":"3413","DOI":"10.1172\/JCI80008","volume":"125","author":"MM Gubin","year":"2015","unstructured":"Gubin, M. M., Artyomov, M. N., Mardis, E. R. & Schreiber, R. D. Tumor neoantigens: building a framework for personalized cancer immunotherapy. J. Clin. Invest. 125, 3413\u20133421 (2015).","journal-title":"J. Clin. Invest."},{"key":"14102_CR4","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1038\/nri.2017.131","volume":"18","author":"Z Hu","year":"2018","unstructured":"Hu, Z., Ott, P. A. & Wu, C. J. Towards personalized, tumour-specific, therapeutic vaccines for cancer. Nat. Rev. Immunol. 18, 168\u2013182 (2018).","journal-title":"Nat. Rev. Immunol."},{"key":"14102_CR5","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1126\/science.aar7112","volume":"359","author":"U Sahin","year":"2018","unstructured":"Sahin, U. & Tureci, O. Personalized vaccines for cancer immunotherapy. Science 359, 1355\u20131360 (2018).","journal-title":"Science"},{"key":"14102_CR6","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1016\/j.smim.2008.09.006","volume":"20","author":"MA Neller","year":"2008","unstructured":"Neller, M. A., Lopez, J. A. & Schmidt, C. W. Antigens for cancer immunotherapy. Semin Immunol. 20, 286\u2013295 (2008).","journal-title":"Semin Immunol."},{"key":"14102_CR7","first-page":"14","volume":"12","author":"J Copier","year":"2010","unstructured":"Copier, J. & Dalgleish, A. Whole-cell vaccines: a failure or a success waiting to happen? Curr. Opin. Mol. Ther. 12, 14\u201320 (2010).","journal-title":"Curr. Opin. Mol. Ther."},{"key":"14102_CR8","doi-asserted-by":"publisher","first-page":"344","DOI":"10.3390\/vaccines3020344","volume":"3","author":"CL Chiang","year":"2015","unstructured":"Chiang, C. L., Coukos, G. & Kandalaft, L. E. Whole tumor antigen vaccines: where are we? Vaccines (Basel) 3, 344\u2013372 (2015).","journal-title":"Vaccines (Basel)"},{"key":"14102_CR9","first-page":"72","volume":"1865","author":"E Ophir","year":"2016","unstructured":"Ophir, E., Bobisse, S., Coukos, G., Harari, A. & Kandalaft, L. E. Personalized approaches to active immunotherapy in cancer. Biochimica. Biophys. Acta 1865, 72\u201382 (2016).","journal-title":"Biochimica. Biophys. Acta"},{"key":"14102_CR10","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1038\/73193","volume":"6","author":"A Kugler","year":"2000","unstructured":"Kugler, A. et al. Regression of human metastatic renal cell carcinoma after vaccination with tumor cell-dendritic cell hybrids. Nat. Med. 6, 332\u2013336 (2000).","journal-title":"Nat. Med."},{"key":"14102_CR11","doi-asserted-by":"publisher","first-page":"2051","DOI":"10.1126\/science.288.5473.2051","volume":"288","author":"PA Oldenborg","year":"2000","unstructured":"Oldenborg, P. A. et al. Role of CD47 as a marker of self on red blood cells. Science 288, 2051 (2000).","journal-title":"Science"},{"key":"14102_CR12","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1182\/blood-2006-04-019794","volume":"109","author":"H Wang","year":"2007","unstructured":"Wang, H. et al. Attenuation of phagocytosis of xenogeneic cells by manipulating CD47. Blood 109, 836\u2013842 (2007).","journal-title":"Blood"},{"key":"14102_CR13","doi-asserted-by":"publisher","first-page":"5062","DOI":"10.1073\/pnas.0609661104","volume":"104","author":"K Ide","year":"2007","unstructured":"Ide, K. et al. Role for CD47-SIRPalpha signaling in xenograft rejection by macrophages. Proc. Natl Acad. Sci. USA 104, 5062\u20135066 (2007).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"14102_CR14","doi-asserted-by":"publisher","first-page":"13744","DOI":"10.1073\/pnas.0702881104","volume":"104","author":"H Wang","year":"2007","unstructured":"Wang, H. et al. Lack of CD47 on nonhematopoietic cells induces split macrophage tolerance to CD47null cells. Proc. Natl Acad. Sci. USA 104, 13744\u201313749 (2007).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"14102_CR15","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1084\/jem.194.4.541","volume":"194","author":"BR Blazar","year":"2001","unstructured":"Blazar, B. R. et al. CD47 (integrin-associated protein) engagement of dendritic cell and macrophage counterreceptors is required to prevent the clearance of donor lymphohematopoietic cells. J. Exp. Med. 194, 541\u2013549 (2001).","journal-title":"J. Exp. Med."},{"key":"14102_CR16","doi-asserted-by":"crossref","first-page":"3401","DOI":"10.4049\/jimmunol.0901550","volume":"184","author":"H Wang","year":"2010","unstructured":"Wang, H., Wu, X., Wang, Y., Oldenborg, P. A. & Yang, Y. G. CD47 is required for suppression of allograft rejection by donor-specific transfusion. J. Immunol. (Baltim., Md : 1950) 184, 3401\u20133407 (2010).","journal-title":"J. Immunol. (Baltim., Md : 1950)"},{"key":"14102_CR17","doi-asserted-by":"publisher","first-page":"355","DOI":"10.3727\/096368912X661346","volume":"23","author":"Y Wang","year":"2014","unstructured":"Wang, Y., Wang, H., Bronson, R., Fu, Y. & Yang, Y. G. Rapid dendritic cell activation and resistance to allotolerance induction in anti-CD154-treated mice receiving CD47-deficient donor-specific transfusion. Cell Transplant. 23, 355\u2013363 (2014).","journal-title":"Cell Transplant."},{"key":"14102_CR18","doi-asserted-by":"publisher","first-page":"345","DOI":"10.3727\/096368913X663604","volume":"23","author":"N Navarro-Alvarez","year":"2014","unstructured":"Navarro-Alvarez, N. & Yang, Y. G. Lack of CD47 on donor hepatocytes promotes innate immune cell activation and graft loss: a potential barrier to hepatocyte xenotransplantation. Cell Transplant. 23, 345\u2013354 (2014).","journal-title":"Cell Transplant."},{"key":"14102_CR19","doi-asserted-by":"publisher","DOI":"10.1038\/srep26839","volume":"6","author":"M Zhang","year":"2016","unstructured":"Zhang, M. et al. Donor CD47 controls T cell alloresponses and is required for tolerance induction following hepatocyte allotransplantation. Sci. Rep. 6, 26839 (2016).","journal-title":"Sci. Rep."},{"key":"14102_CR20","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1002\/hep.24652","volume":"55","author":"DM Avella","year":"2012","unstructured":"Avella, D. M. et al. Regression of established hepatocellular carcinoma is induced by chemoimmunotherapy in an orthotopic murine model. Hepatology 55, 141\u2013152 (2012).","journal-title":"Hepatology"},{"key":"14102_CR21","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1111\/j.1440-1746.1996.tb00006.x","volume":"11","author":"D Kuruppu","year":"1996","unstructured":"Kuruppu, D., Christophi, C., Bertram, J. F. & O'Brien, P. E. Characterization of an animal model of hepatic metastasis. J. Gastroenterol. Hepatol. 11, 26\u201332 (1996).","journal-title":"J. Gastroenterol. Hepatol."},{"key":"14102_CR22","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.cell.2016.10.044","volume":"168","author":"AC Komor","year":"2017","unstructured":"Komor, A. C., Badran, A. H. & Liu, D. R. CRISPR-based technologies for the manipulation of eukaryotic genomes. Cell 168, 20\u201336 (2017).","journal-title":"Cell"},{"key":"14102_CR23","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1038\/nature26155","volume":"556","author":"JH Hu","year":"2018","unstructured":"Hu, J. H. et al. Evolved Cas9 variants with broad PAM compatibility and high DNA specificity. Nature 556, 57\u201363 (2018).","journal-title":"Nature"},{"key":"14102_CR24","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1016\/j.immuni.2016.08.015","volume":"45","author":"M Guilliams","year":"2016","unstructured":"Guilliams, M. et al. Unsupervised high-dimensional analysis aligns dendritic cells across tissues and species. Immunity 45, 669\u2013684 (2016).","journal-title":"Immunity"},{"key":"14102_CR25","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/S1074-7613(02)00365-5","volume":"17","author":"S Jung","year":"2002","unstructured":"Jung, S. et al. In vivo depletion of CD11c+ dendritic cells abrogates priming of CD8+ T cells by exogenous cell-associated antigens. Immunity 17, 211\u2013220 (2002).","journal-title":"Immunity"},{"key":"14102_CR26","doi-asserted-by":"crossref","first-page":"4371","DOI":"10.4049\/jimmunol.181.6.4371","volume":"181","author":"T Fehr","year":"2008","unstructured":"Fehr, T. et al. Rapid deletional peripheral CD8 T cell tolerance induced by allogeneic bone marrow: role of donor class II MHC and B cells. J. Immunol. (Baltim., Md : 1950) 181, 4371\u20134380 (2008).","journal-title":"J. Immunol. (Baltim., Md : 1950)"},{"key":"14102_CR27","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1016\/j.cell.2009.05.045","volume":"138","author":"R Majeti","year":"2009","unstructured":"Majeti, R. et al. CD47 is an adverse prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells. Cell 138, 286\u2013299 (2009).","journal-title":"Cell"},{"key":"14102_CR28","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.cell.2009.05.046","volume":"138","author":"S Jaiswal","year":"2009","unstructured":"Jaiswal, S. et al. CD47 is upregulated on circulating hematopoietic stem cells and leukemia cells to avoid phagocytosis. Cell 138, 271\u2013285 (2009).","journal-title":"Cell"},{"key":"14102_CR29","doi-asserted-by":"publisher","first-page":"14016","DOI":"10.1073\/pnas.0906549106","volume":"106","author":"KS Chan","year":"2009","unstructured":"Chan, K. S. et al. Identification, molecular characterization, clinical prognosis, and therapeutic targeting of human bladder tumor-initiating cells. Proc. Natl Acad. Sci. USA 106, 14016\u201314021 (2009).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"14102_CR30","doi-asserted-by":"publisher","first-page":"6662","DOI":"10.1073\/pnas.1121623109","volume":"109","author":"SB Willingham","year":"2012","unstructured":"Willingham, S. B. et al. The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors. Proc. Natl Acad. Sci. USA 109, 6662\u20136667 (2012).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"14102_CR31","doi-asserted-by":"publisher","first-page":"2610","DOI":"10.1172\/JCI81603","volume":"126","author":"K Weiskopf","year":"2016","unstructured":"Weiskopf, K. et al. CD47-blocking immunotherapies stimulate macrophage-mediated destruction of small-cell lung cancer. J. Clin. Invest 126, 2610\u20132620 (2016).","journal-title":"J. Clin. Invest"},{"key":"14102_CR32","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1016\/j.cell.2010.07.044","volume":"142","author":"MP Chao","year":"2010","unstructured":"Chao, M. P. et al. Anti-CD47 antibody synergizes with rituximab to promote phagocytosis and eradicate non-Hodgkin lymphoma. Cell 142, 699\u2013713 (2010).","journal-title":"Cell"},{"key":"14102_CR33","doi-asserted-by":"publisher","first-page":"e0137345","DOI":"10.1371\/journal.pone.0137345","volume":"10","author":"J Liu","year":"2015","unstructured":"Liu, J. et al. Pre-clinical development of a humanized anti-CD47 antibody with anti-cancer therapeutic potential. PloS ONE 10, e0137345 (2015).","journal-title":"PloS one"},{"key":"14102_CR34","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1038\/nature18935","volume":"536","author":"Y Kojima","year":"2016","unstructured":"Kojima, Y. et al. CD47-blocking antibodies restore phagocytosis and prevent atherosclerosis. Nature 536, 86\u201390 (2016).","journal-title":"Nature"},{"key":"14102_CR35","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1038\/nm.3931","volume":"21","author":"X Liu","year":"2015","unstructured":"Liu, X. et al. CD47 blockade triggers T cell-mediated destruction of immunogenic tumors. Nat. Med. 21, 1209\u20131215 (2015).","journal-title":"Nat. Med."},{"key":"14102_CR36","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1146\/annurev-immunol-020711-074950","volume":"31","author":"M Merad","year":"2013","unstructured":"Merad, M., Sathe, P., Helft, J., Miller, J. & Mortha, A. The dendritic cell lineage: ontogeny and function of dendritic cells and their subsets in the steady state and the inflamed setting. Annu. Rev. Immunol. 31, 563\u2013604 (2013).","journal-title":"Annu. Rev. Immunol."},{"key":"14102_CR37","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1016\/j.immuni.2016.03.012","volume":"44","author":"H Salmon","year":"2016","unstructured":"Salmon, H. et al. Expansion and activation of CD103(+) dendritic cell progenitors at the tumor site enhances tumor responses to therapeutic PD-L1 and BRAF inhibition. Immunity 44, 924\u2013938 (2016).","journal-title":"Immunity"},{"key":"14102_CR38","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1136\/gutjnl-2014-307916","volume":"65","author":"ER Mann","year":"2016","unstructured":"Mann, E. R. et al. Compartment-specific immunity in the human gut: properties and functions of dendritic cells in the colon versus the ileum. Gut 65, 256\u2013270 (2016).","journal-title":"Gut"}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-019-14102-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-019-14102-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-019-14102-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,5]],"date-time":"2022-12-05T17:40:57Z","timestamp":1670262057000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-019-14102-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,29]]},"references-count":38,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,12]]}},"alternative-id":["14102"],"URL":"https:\/\/doi.org\/10.1038\/s41467-019-14102-4","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1,29]]},"assertion":[{"value":"11 October 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 December 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 January 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"581"}}